Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDX NASDAQ:AVDL NASDAQ:FULC NASDAQ:JANX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDXArdelyx$6.36-0.3%$4.84$3.21▼$7.18$1.54B0.684.55 million shs2.37 million shsAVDLAvadel Pharmaceuticals$14.76+1.0%$11.44$6.38▼$16.66$1.42B1.471.34 million shs1.65 million shsFULCFulcrum Therapeutics$6.48-2.6%$7.11$2.32▼$9.30$359.71M2.47524,116 shs181,855 shsJANXJanux Therapeutics$22.72-1.4%$24.52$21.97▼$71.71$1.39B2.86814,947 shs456,346 shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDXArdelyx+3.07%+4.42%+51.18%+71.51%+3.74%AVDLAvadel Pharmaceuticals-1.68%-1.35%+37.54%+60.13%-1.62%FULCFulcrum Therapeutics+0.30%+1.99%-12.38%-3.06%-25.03%JANXJanux Therapeutics-1.28%-3.96%-4.63%-2.78%-47.86%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationARDXArdelyx4.1094 of 5 stars3.52.00.04.41.92.50.6AVDLAvadel Pharmaceuticals2.8817 of 5 stars3.63.00.00.02.91.70.6FULCFulcrum Therapeutics0.8746 of 5 stars2.31.00.00.02.21.70.0JANXJanux Therapeutics2.7307 of 5 stars3.53.00.00.03.71.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDXArdelyx 3.00Buy$11.5080.82% UpsideAVDLAvadel Pharmaceuticals 3.14Buy$19.6733.24% UpsideFULCFulcrum Therapeutics 2.63Moderate Buy$7.5716.84% UpsideJANXJanux Therapeutics 3.08Buy$86.90282.48% UpsideCurrent Analyst Ratings BreakdownLatest FULC, AVDL, ARDX, and JANX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/21/2025AVDLAvadel PharmaceuticalsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$13.00 ➝ $20.008/18/2025JANXJanux TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOverweight$42.008/8/2025AVDLAvadel PharmaceuticalsDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy8/8/2025AVDLAvadel PharmaceuticalsZacks ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy8/8/2025AVDLAvadel PharmaceuticalsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$22.00 ➝ $24.008/6/2025ARDXArdelyxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetNeutral ➝ Neutral$8.00 ➝ $9.008/5/2025ARDXArdelyxUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price Target$12.008/5/2025ARDXArdelyxRaymond James FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$11.00 ➝ $12.008/5/2025ARDXArdelyxWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$13.00 ➝ $14.007/30/2025FULCFulcrum TherapeuticsRoyal Bank Of CanadaSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetSector Perform ➝ Sector Perform$4.00 ➝ $5.007/29/2025FULCFulcrum TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeNeutral ➝ Buy$4.00 ➝ $12.00(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDXArdelyx$333.61M4.59N/AN/A$0.58 per share10.97AVDLAvadel Pharmaceuticals$169.12M8.47N/AN/A$0.93 per share15.87FULCFulcrum TherapeuticsN/AN/AN/AN/A$3.96 per shareN/AJANXJanux Therapeutics$10.59M128.92N/AN/A$16.48 per share1.38Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDXArdelyx-$39.14M-$0.23N/A20.52N/A-14.60%-36.57%-13.42%10/30/2025 (Estimated)AVDLAvadel Pharmaceuticals-$48.83M-$0.03N/A246.00N/A-1.32%-3.73%-1.73%11/11/2025 (Estimated)FULCFulcrum Therapeutics-$9.73M-$1.22N/AN/AN/AN/A-31.05%-28.96%11/12/2025 (Estimated)JANXJanux Therapeutics-$68.99M-$1.80N/AN/AN/AN/A-11.48%-11.01%11/5/2025 (Estimated)Latest FULC, AVDL, ARDX, and JANX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025AVDLAvadel Pharmaceuticals$0.02$0.10+$0.08$0.10$60.28 million$68.13 million8/7/2025Q2 2025JANXJanux Therapeutics-$0.48-$0.55-$0.07-$0.55$0.30 millionN/A8/4/2025Q2 2025ARDXArdelyx-$0.13-$0.08+$0.05-$0.08$82.69 million$97.66 million7/29/2025Q2 2025FULCFulcrum Therapeutics-$0.29-$0.28+$0.01-$0.28N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDXArdelyxN/AN/AN/AN/AN/AAVDLAvadel PharmaceuticalsN/AN/AN/AN/AN/AFULCFulcrum TherapeuticsN/AN/AN/AN/AN/AJANXJanux TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDXArdelyx1.444.304.03AVDLAvadel PharmaceuticalsN/A2.792.38FULCFulcrum TherapeuticsN/A24.4224.42JANXJanux TherapeuticsN/A47.0347.03Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDXArdelyx58.92%AVDLAvadel Pharmaceuticals69.19%FULCFulcrum Therapeutics89.83%JANXJanux Therapeutics75.39%Insider OwnershipCompanyInsider OwnershipARDXArdelyx4.80%AVDLAvadel Pharmaceuticals5.20%FULCFulcrum Therapeutics7.00%JANXJanux Therapeutics8.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDXArdelyx90240.98 million229.42 millionOptionableAVDLAvadel Pharmaceuticals7097.10 million92.05 millionOptionableFULCFulcrum Therapeutics10054.09 million50.31 millionOptionableJANXJanux Therapeutics3060.09 million55.23 millionOptionableFULC, AVDL, ARDX, and JANX HeadlinesRecent News About These CompaniesJump Financial LLC Takes Position in Janux Therapeutics, Inc. $JANXAugust 29 at 5:19 AM | marketbeat.comJanux Therapeutics, Inc. $JANX Stock Holdings Cut by Invesco Ltd.August 29 at 3:23 AM | marketbeat.comBTIG Reaffirms Their Buy Rating on Janux Therapeutics Inc (JANX)August 27 at 11:47 PM | theglobeandmail.comVanguard Group Inc. Has $61.52 Million Stock Holdings in Janux Therapeutics, Inc. $JANXAugust 26 at 3:20 AM | marketbeat.comAlgert Global LLC Reduces Stock Position in Janux Therapeutics, Inc. $JANXAugust 25, 2025 | marketbeat.comRussell Investments Group Ltd. Purchases 152,837 Shares of Janux Therapeutics, Inc. $JANXAugust 25, 2025 | marketbeat.comErste Asset Management GmbH Invests $786,000 in Janux Therapeutics, Inc. $JANXAugust 24, 2025 | marketbeat.comJanux Therapeutics, Inc. $JANX Shares Purchased by Aberdeen Group plcAugust 23, 2025 | marketbeat.comPiper Sandler Initiates Coverage of Janux Therapeutics (JANX) with Overweight RecommendationAugust 20, 2025 | msn.comJanux Therapeutics initiated with an Overweight at Piper SandlerAugust 19, 2025 | msn.comPiper starts Janux Therapeutics with an Overweight on ‘best-in-class’ potentialAugust 19, 2025 | msn.comJanux Therapeutics, Inc. (NASDAQ:JANX) Shares Sold by Lord Abbett & CO. LLCAugust 18, 2025 | marketbeat.comQ3 EPS Estimate for Janux Therapeutics Reduced by AnalystAugust 16, 2025 | marketbeat.comHC Wainwright Expects Higher Earnings for Janux TherapeuticsAugust 14, 2025 | marketbeat.comHC Wainwright Has Bearish Estimate for JANX FY2029 EarningsAugust 13, 2025 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Given Average Recommendation of "Buy" by BrokeragesAugust 11, 2025 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Reaches New 12-Month Low After Earnings MissAugust 9, 2025 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Trading 8.6% Higher - Here's What HappenedAugust 6, 2025 | marketbeat.comJanux Therapeutics Announces Clinical Milestone Achievement in TRACTr Collaboration With MerckAugust 5, 2025 | businesswire.comJanux Therapeutics, Inc. (NASDAQ:JANX) Stock Position Decreased by TD Asset Management IncAugust 5, 2025 | marketbeat.comJanux Therapeutics (JANX) Expected to Announce Quarterly Earnings on WednesdayJuly 31, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeFULC, AVDL, ARDX, and JANX Company DescriptionsArdelyx NASDAQ:ARDX$6.36 -0.02 (-0.31%) Closing price 04:00 PM EasternExtended Trading$6.34 -0.02 (-0.33%) As of 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.Avadel Pharmaceuticals NASDAQ:AVDL$14.76 +0.14 (+0.96%) Closing price 04:00 PM EasternExtended Trading$15.05 +0.29 (+1.99%) As of 06:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is LUMRYZ, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness or cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.Fulcrum Therapeutics NASDAQ:FULC$6.48 -0.17 (-2.56%) Closing price 04:00 PM EasternExtended Trading$6.59 +0.11 (+1.70%) As of 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.Janux Therapeutics NASDAQ:JANX$22.72 -0.33 (-1.43%) Closing price 04:00 PM EasternExtended Trading$22.72 0.00 (0.00%) As of 05:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access